

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/089,024	LEHMANN-LINTZ ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Emily Bernhardt	1624	

**All Participants:**

(1) Emily Bernhardt.

(2) Mr. Anthony Bottino.

**Date of Interview:** 27 July 2004

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_.

(4) \_\_\_\_\_.

**Time:** \_\_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

*11 in particular*

Prior art documents discussed:

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*In urging support for newly added rings it was pointed out to counsel that "thiazolyl" is not exemplified in eg.38 but rather 1,2,4 thiadiazolyl. It was agreed to replace the former with the latter ring in claim 11 via an Examiner's Amendment.*

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Bottino on July 27, 2004.

1. In claim 11 on p.2 on the 8<sup>th</sup> line, delete "thiazolyl" and insert in its place

- - - 1,2,4 thiadiazolyl - - - .

2. In claim 11 on p.3 on the 5<sup>th</sup> line, delete "thiazolyl" and insert in its place

- - - 1,2,4 thiadiazolyl - - - .

The following word processing typo is also being corrected:

3. In claim 11 on p.3 on the 8<sup>th</sup> line after "R<sub>f</sub> denotes" delete " $\frac{r}{r}$ " .

**Cusic (US'509) cited in applicants' IDS filed 3/14/02 was inadvertently not considered and so is cited on a PTO-892 accompanying this action.**

Bernhardt:eb

(571)272-0664

Application/Control Number: 10/089,024  
Art Unit: 1624

Page 3

8/2/04

*E Bernhardt*

EMILY BERNHARDT  
PRIMARY EXAMINER  
GROUP ~~120~~ / 600